Clinical Trial Update: Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of everolimus (RAD001) as primary therapy for Waldenstrom's Macroglobulinemia completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Waldenstrom's Macroglobulinemia | Phase 2 | Status: COMPLETED | Results posted: 2014-06-16